Evidence map›Paper›PMID 38183616›Full record

ReviewDermatology and therapy2024

Burden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported Outcomes.

Alexa B Kimball, Joslyn Kirby, John R Ingram, Tanja Tran, Ingrid Pansar, Valerie Ciaravino, Damon Willems, Anne-Mary Lewis-Mikhael, Vanita Tongbram, Amit Garg

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Dermatology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
20.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Patient journey and disparities in the diagnosis and treatment of patients with hidradenitis suppurativa.JID innovations : skin science from molecules to population health · 2026
    Article
  9. Review
  10. Article
  11. Article
  12. Observational
  13. Article
  14. The Genetics of Hidradenitis Suppurativa.Clinical, cosmetic and investigational dermatology · 2026
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 5 countries.

Alexa B KimballHarvard Medical School and Beth Israel Deaconess Medical Center Boston, Boston, MA, USA. clears@bidmc.harvard.edu.ORCID http://orcid.org/0000-0001-9405-0479
Joslyn KirbyPenn State University, Philadelphia, PA, USA.
John R IngramCardiff University, Cardiff, Wales.
Tanja TranUCB Pharma, Brussels, Belgium.
Ingrid PansarUCB Pharma, Brussels, Belgium.
Valerie CiaravinoUCB Pharma, Colombes, France.
Damon WillemsUCB Pharma, Brussels, Belgium.
Anne-Mary Lewis-MikhaelICON Plc, Dublin, Ireland.
Vanita TongbramICON Plc, Dublin, Ireland.
Amit GargNorthwell Health, New Hyde Park, New York, NY, USA.ORCID http://orcid.org/0000-0003-0886-6856
UCB Pharma (Belgium) · BEBeth Israel Deaconess Medical Center · USNorthwell Health · USPennsylvania State University · USUCB Pharma (France) · FRUniversity of Wales Institute Cardiff · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHidradenitis suppurativa (HS) has a profound negative impact on patients' health-related quality of life (HRQoL). Here we summarize the evidence on HRQoL and Patient Reported Outcomes (PROs) in patients with HS in real-world settings by conducting a systematic literature review (SLR) of observational studies.

methodsData sources included MEDLINE, Embase & PsycINFO between January 1, 2010 and August 29, 2021, and conference proceedings between 2019 and 2021. Identified abstracts were reviewed and screened independently by two reviewers. Eligibility criteria included patients with HS of any severity, sample size ≥ 100, reporting PROs including HRQoL measures. Included studies were critically appraised.

resultsFifty-eight observational studies matched inclusion criteria. Dermatology Life Quality Index (DLQI) was the most commonly utilized instrument: 57% of included studies reported mean baseline DLQI scores, ranging between 8.4 and 16.9, indicating a very large impact on the patients' HRQoL. Higher scores were reported with increasing disease severity and among female patients. Pain was assessed mostly by an 11-point (0-10) numeric rating scale (NRS) with a mean baseline score ranging from 3.6 to 7.7 indicating moderate to high pain levels. There was a negative impact of HS on patients' psychological well-being, based on PRO scores related to depression and anxiety. A high proportion of sexual dysfunction was reported, with a larger impact on women than men. Work productivity and leisure activity were consistently found to be impaired in patients with HS.

conclusionsAll included studies reported a negative impact of HS on patients' lives. A diverse set of disease- and non-disease-specific PRO instruments were utilized highlighting the need for more consistent use of HS-specific validated PRO instruments to assess the impact of HS on the different aspects of patients' HRQoL to allow for data to be more meaningfully interpreted and compared in real-world settings. Patients with HS need better disease management approaches that address the observed low quality of life.

Indexed as

Hidradenitis suppurativaImpactQuality of lifeReal-world evidence

Identifiers

PMID38183616
PMCPMC10828455
OpenAlexW4390640132

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.